FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
0:00
3:30
Listen to a soundcast of the May 19, 2023, FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Fler avsnitt från "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Missa inte ett avsnitt av “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” och prenumerera på det i GetPodcast-appen.